M. Stacey Ricci

Analysis of Suffix Use for Biosimilar Product Identification in Postmarketing Adverse Event Reporting

Accurate identification of medicines used in adverse event reports is crucial for effective postmarketing safety surveillance. The US Food and Drug Administration's (FDA) four‐letter suffix naming convention was designed to facilitate accurate biological product identification, b...